Semaglutide Use Guidelines

Indications and Age Restrictions

Semaglutide is approved for adults with type 2 diabetes, with no upper age limit specified by the American Diabetes Association, and clinical trials included patients with mean ages in the 60s 1, 2, 3
For weight management, semaglutide is approved for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, and pediatric patients ages 12 and older with obesity 2
The FDA-approved age range for Ozempic (semaglutide) is adults 18 years and older with type 2 diabetes, while Wegovy (semaglutide) is approved for weight management in patients 12 years and older with obesity 1, 2

Dose adjustments based on age alone are not required, but caution is advised in elderly patients due to potential increased susceptibility to gastrointestinal side effects, according to the American Diabetes Association guidelines 1, 2
No specific upper age limit exists for Ozempic use, and clinical trials typically included patients up to their 70s and 80s, with a mean age range of 64-66 years in cardiovascular outcomes trials 1, 2, 3

The American Diabetes Association recommends verifying patient age (≥18 years old for diabetes management) and documenting absence of contraindications, including personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), when prescribing Ozempic 1, 2
Eligibility criteria for GLP-1 receptor agonists include:
The American Diabetes Association, American Gastroenterological Association, and Obesity Society recommend documenting medical necessity, including inadequate glycemic control or inability to achieve or maintain clinically significant weight loss, for patients with type 2 diabetes or obesity 4, 5, 6
The European Society of Cardiology and American Heart Association recommend assessing cardiovascular risk factors, including established cardiovascular disease, blood pressure readings, lipid profile, and smoking status, in patients eligible for GLP-1 receptor agonists 4, 7
The American Thyroid Association, Endocrine Society, and American Gastroenterological Association recommend documenting absence of personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and pancreatitis before initiating GLP-1 receptor agonists 8

The American Diabetes Association, Obesity Society, and European Society of Cardiology recommend setting specific treatment goals, including HbA1c targets and weight loss targets, and monitoring parameters, such as weight, HbA1c, and side effects, to assess treatment success 4, 5, 6, 8
The American Association of Clinical Endocrinologists, American Heart Association, and American Gastroenterological Association recommend scheduling follow-up appointments to monitor treatment response, typically every 3-6 months, and assessing treatment response, including weight loss and HbA1c improvement, to determine continued coverage 4, 7, 8